Amarillo Biosciences Licenses Low Dose Oral Interferon to Global Kinetics for Sale in Three Countries in SE Asia
Avian Flu Fuels Interest in Low Dose Oral Interferon as Potential Therapy
Interest in the Company's low dose oral interferon has risen with international concern about the potential of the current bird flu outbreak to develop into a pandemic. Health care professionals agree that the public is vulnerable to the pending influenza pandemic. Effective vaccination for influenza is the goal of health officials. However, no vaccine is yet available for the H5N1 virus (bird flu), and the therapies that do exist, such as Tamiflu, are in limited supply worldwide. Consequently, ABI and Global Kinetics are working together to bring a promising new prevention and treatment option for influenza to the developing world. Global Kinetics intends to market ABI's low dose oral interferon through a Cambodian company (Global Kinetics of Cambodia). "
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.